




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶: C07C 237/22, 259/06, A61K 31/16	A1	(11) International Publication Number: WO 99/35124 (43) International Publication Date: 15 July 1999 (15.07.99)
(21) International Application Number: PCT/EP98/08565 (22) International Filing Date: 23 December 1998 (23.12.98) (30) Priority Data: 9800510.1 9 January 1998 (09.01.98) GB 9811843.3 2 June 1998 (02.06.98) GB (71) Applicant (for GB only): PFIZER LIMITED [GB/GB]; Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). (71) Applicant (for all designated States except GB US): PFIZER, INC. [US/US]; 235 East 42nd Street, New York, NY 10017 (US). (72) Inventors; and (75) Inventors/Applicants (for US only): FRAY, Michael, Jonathan [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). DICKINSON, Roger, Peter [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). DACK, Kevin, Neil [GB/GB]; Pfizer Central Research, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB). (74) Agents: WOOD, David, John et al.; Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ (GB).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: MATRIX METALLOPROTEASE INHIBITORS  (I) (57) Abstract Compounds of formula (I) or pharmaceutically acceptable salts thereof, or solvates of either entity, wherein the substituents have the values described herein, are useful as matrix metalloprotease (MMP) inhibitors.		